Richard Nolan Townsend - 18 Feb 2026 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Executive Officer, Director
Signature
/s/ Carole Rosenberg, Attorney-in-Fact
Issuer symbol
LXEO
Transactions as of
18 Feb 2026
Net transactions value
-$64,924
Form type
4
Filing time
20 Feb 2026, 17:05:07 UTC
Previous filing
06 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Townsend Richard Nolan Chief Executive Officer, Director C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK /s/ Carole Rosenberg, Attorney-in-Fact 20 Feb 2026 0001995218

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Sale $64,924 -10,173 -2.5% $6.38 392,483 18 Feb 2026 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
F2 This transaction was executed in multiple trades at prices ranging from $6.22 to $6.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 Includes 261,349 Restricted Stock Units.